Related references
Note: Only part of the references are listed.GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)
Ali H. Mokdad
LANCET NEUROLOGY (2021)
Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database
Roberta Noseda et al.
CEPHALALGIA (2021)
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial
Messoud Ashina et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2
Hans-Christoph Diener et al.
HEADACHE (2021)
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study
Piero Barbanti et al.
HEADACHE (2021)
Association between response to triptans and response to erenumab: real-life data
Ilaria Frattale et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Immunogenicity of biologic therapies for migraine: a review of current evidence
Joshua M. Cohen et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
Robert Croop et al.
LANCET (2021)
Sex Differences in Response to Triptans A Systematic Review and Meta-analysis
Daphne S. van Casteren et al.
NEUROLOGY (2021)
Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial
Ramesh Boinpally et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
Migraine therapeutics differentially modulate the CGRP pathway
Minoti Bhakta et al.
CEPHALALGIA (2021)
Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications
Simone de Vries Lentsch et al.
MATURITAS (2021)
Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients
Hashmat Ghanizada et al.
ANNALS OF NEUROLOGY (2021)
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II
Susan Hutchinson et al.
CEPHALALGIA (2021)
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
Andrew M. Blumenfeld et al.
HEADACHE (2021)
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study
Abhijeet Jakate et al.
HEADACHE (2021)
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
Fabrizio Vernieri et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
David W. Dodick et al.
CEPHALALGIA (2021)
Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
William Kielbasa et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries
Eloisa Rubio-Beltran et al.
CEPHALALGIA (2020)
Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
Abhijeet Jakate et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial
Jessica Ailani et al.
HEADACHE (2020)
Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor
Eric Moore et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
Kathleen Mullin et al.
NEUROLOGY (2020)
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses
Jill Fiedler-Kelly et al.
HEADACHE (2020)
Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
Wendy Ankrom et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Cardiovascular effects and safety of (non-aspirin) NSAIDs
Anne-Marie Schjerning et al.
NATURE REVIEWS CARDIOLOGY (2020)
Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
David Moreno-Ajona et al.
CURRENT OPINION IN NEUROLOGY (2020)
Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool
Lisa Cheng et al.
PHARMACEUTICS (2020)
Predicting erenumab adverse events with single-cell genomics
Angeliki Vgontzas et al.
LANCET (2020)
Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine
Jennifer Robblee et al.
HEADACHE (2020)
No Wearing-Off Effect Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study
Andrew M. Blumenfeld et al.
HEADACHE (2020)
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
Stephen D. Silberstein et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Targeting CGRP in migraine: a matter of choice and dose
Linda Al-Hassany et al.
LANCET NEUROLOGY (2020)
COULD OBESITY HINDER A CORONAVIRUS VACCINE?
Heidi Ledford
NATURE (2020)
Erenumab efficacy in highly resistant chronic migraine: a real-life study
Umberto Pensato et al.
NEUROLOGICAL SCIENCES (2020)
Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study
Francesca Schiano di Cola et al.
NEUROLOGICAL SCIENCES (2020)
Antagonism of CGRP Signaling by Rimegepant at Two Receptors
Kylie S. Pan et al.
FRONTIERS IN PHARMACOLOGY (2020)
Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
Danuta Szkutnik-Fiedler
PHARMACEUTICS (2020)
Distinct Patterns of Internalization of Different Calcitonin GeneRelated Peptide Receptors
Joseph J. Gingell et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Valentina Favoni et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related
Yelena Guttman et al.
FRONTIERS IN GENETICS (2019)
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Peter J. Goadsby et al.
CEPHALALGIA (2019)
Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class
Richard Hargreaves et al.
HEADACHE (2019)
Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking
Raffi Manoukian et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Malnutrition in the elderly
Clodagh Corcoran et al.
SCIENCE PROGRESS (2019)
Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine
Jeanine L. Bussiere et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2019)
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine The ACHIEVE II Randomized Clinical Trial
Richard B. Lipton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Targeting calcitonin gene-related peptide: a new era in migraine therapy
Andrew Charles et al.
LANCET (2019)
CGRP, Amylin, Immunology, and Headache Medicine
Frederick R. Taylor
HEADACHE (2019)
Ubrogepant for the Treatment of Migraine
David W. Dodick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Gender aspects of CGRP in migraine
Alejandro Labastida-Ramirez et al.
CEPHALALGIA (2019)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects
Zizheng Kee et al.
FRONTIERS IN PHYSIOLOGY (2018)
Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Joseph Raymond Zunt et al.
LANCET NEUROLOGY (2018)
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lars Jacob Stovner et al.
LANCET NEUROLOGY (2018)
Blocking CGRP in migraine patients - a review of pros and cons
Marie Deen et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects
Thuy Vu et al.
PHARMACEUTICAL RESEARCH (2017)
BDDCS, the Rule of 5 and drugability
Leslie Z. Benet et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations
Luana Lionetto et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Wiping Out CGRP: Potential Cardiovascular Risks
Antoinette MaassenVanDenBrink et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies
G. Roberto et al.
CEPHALALGIA (2015)
A second trigeminal CGRP receptor: function and expression of the AMY1 receptor
Christopher S. Walker et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Pharmacokinetics
Jianghong Fan et al.
BIOCHEMICAL PHARMACOLOGY (2014)
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
Ronald Marcus et al.
CEPHALALGIA (2014)
The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development
Leslie Z. Benet
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Pharmacokinetics of Drugs in Cachectic Patients: A Systematic Review
Katja Trobec et al.
PLOS ONE (2013)
IgG Placental Transfer in Healthy and Pathological Pregnancies
Patricia Palmeira et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2)
Ichiro Ieiri
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Michael J. Hanley et al.
CLINICAL PHARMACOKINETICS (2010)
Sex Differences in Pharmacokinetics and Pharmacodynamics
Offie P. Soldin et al.
CLINICAL PHARMACOKINETICS (2009)
Migraine prevalence in eating disorders and pathophysiological correlations
Giovanni D'Andrea et al.
NEUROLOGICAL SCIENCES (2009)
Migraine headaches and preeclampsia: An epidemiologic review
KL Adeney et al.
HEADACHE (2006)
Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack
G Juhasz et al.
CEPHALALGIA (2005)
The influence of age and sex on the clearance of cytochrome P450 3A substrates
MM Cotreau et al.
CLINICAL PHARMACOKINETICS (2005)
Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system
CY Wu et al.
PHARMACEUTICAL RESEARCH (2005)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Volumes of distribution
PL Toutain et al.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS (2004)
Share Paper
